Category: Assay Development and Screening

1081-B - The CC Microplate: High-content Imaging and Assay Platform for 3D Cell Cultures

Monday, February 5, 2018
5:00 PM - 6:00 PM

Early drug discovery has historically been conducted in 2D, but the advent of 3D cell culture has improved the predictive power of drug screening and generated more accurate “hits” for drug candidates. Various scaffold-free 3D cell culture platforms are available, but our plate technology, the CC Microplate, creates a large number of spheroids that can also be imaged and assayed all in the same microplate. In a 384-well CC Microplate, 150 spheroids were created in each well with a size limit of 200 µM in diameter. Viability was assessed by ATP content (CellTiter-Glo) and fluorescent imaging (Calcein AM/Propidium Iodide). Compared to competitor 3D cell culture plates, the CC Microplate reduced background fluorescence allowing for higher quality images. Additionally, smaller, size restricted spheroids were generated from the CC Microplate which reduced hypoxic core necrosis. Overall, spheroids were quickly and easily produced and various assay were compatible with our 3D drug discovery platform, the CC Microplate.

Karthik Ramachandran

Vice President and Co-Founder
Likarda, LLC
Kansas City, MO

With a Ph.D. in bioengineering and a knack for entrepreneurship, Karthik Ramachandran is the co-founder and vice president of Likarda, a world-class biotech research laboratory for science entrepreneurs, partners for bio consortiums, and contract research organizations. His graduate research focused on tissue engineering, specifically developing a technology for efficiently engineering 3D cell clusters (or miniature organs) for applications in drug discovery and regenerative medicine that can benefit animal and human health.

That research became the foundation for Likarda. The original proof-of-concept studies focused on the notion of re-engineering the 3D structure of islets to minimize diffusion barriers and increase viability and performance, with an end result being a superior transplantable solution for treating diabetes. Karthik has been published in many peer-reviewed publications on diabetes, islets, and engineering of tissue, with a few focusing on drug discovery. He also is a primary inventor in several pending/issued US and International patents.

Karthik has been recognized with entrepreneurial awards, including “20 in Their Twenties” from Ingram’s Magazine and was named a “Top Young Entrepreneur to Watch” by Under30CEO and featured in several national news articles over the last few years as Likarda grew from a start-up to a profitable small business. He sits on various boards and advisory boards that support the growing bioscience industry in the Kansas City region and the U.S. Since co-founding Likarda, he has been involved in business development and corporate partnerships.